LLY

1,053.56

+0.58%↑

JNJ

203.14

+0.75%↑

ABBV

228.97

-2.26%↓

UNH

312.5

+2.49%↑

AZN

89.67

+0.68%↑

LLY

1,053.56

+0.58%↑

JNJ

203.14

+0.75%↑

ABBV

228.97

-2.26%↓

UNH

312.5

+2.49%↑

AZN

89.67

+0.68%↑

LLY

1,053.56

+0.58%↑

JNJ

203.14

+0.75%↑

ABBV

228.97

-2.26%↓

UNH

312.5

+2.49%↑

AZN

89.67

+0.68%↑

LLY

1,053.56

+0.58%↑

JNJ

203.14

+0.75%↑

ABBV

228.97

-2.26%↓

UNH

312.5

+2.49%↑

AZN

89.67

+0.68%↑

LLY

1,053.56

+0.58%↑

JNJ

203.14

+0.75%↑

ABBV

228.97

-2.26%↓

UNH

312.5

+2.49%↑

AZN

89.67

+0.68%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

40.63 0.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.21

Max

40.96

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+36.75% upside

Turustatistika
By TradingEconomics
Turukapital	-92M 3.1B
Eelmine avamishind	40.43
Eelmine sulgemishind	40.63

Uudiste sentiment

By Acuity

50%

177 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. nov 2025, 23:36 UTC

Kuumad aktsiad

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19. nov 2025, 22:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19. nov 2025, 21:55 UTC

Suurimad hinnamuutused turgudel

Amgen Lung Cancer Drug Gets Full Approval From FDA

19. nov 2025, 21:43 UTC

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19. nov 2025, 23:55 UTC

Market Talk

Gold Rises on Possible Investment Demand -- Market Talk

19. nov 2025, 23:54 UTC

Market Talk

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19. nov 2025, 23:47 UTC

Tulu

Lenovo Group 2Q EPS $2.52 >0992.HK

19. nov 2025, 23:46 UTC

Tulu

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19. nov 2025, 23:45 UTC

Tulu

Lenovo Group 2Q Rev $20.5B >0992.HK

19. nov 2025, 23:42 UTC

Market Talk

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19. nov 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

19. nov 2025, 23:41 UTC

Tulu

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19. nov 2025, 23:41 UTC

Tulu

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19. nov 2025, 23:40 UTC

Tulu

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19. nov 2025, 22:55 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19. nov 2025, 22:41 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19. nov 2025, 22:30 UTC

Omandamised, ülevõtmised, äriostud

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19. nov 2025, 22:30 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19. nov 2025, 22:30 UTC

Omandamised, ülevõtmised, äriostud

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19. nov 2025, 22:27 UTC

Omandamised, ülevõtmised, äriostud

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19. nov 2025, 22:08 UTC

Tulu

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19. nov 2025, 22:00 UTC

Tulu

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19. nov 2025, 21:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19. nov 2025, 21:52 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

19. nov 2025, 21:49 UTC

Market Talk

Tulu

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19. nov 2025, 21:38 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19. nov 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35B

19. nov 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19. nov 2025, 21:24 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

36.75% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 36.75%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

177 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.